There are 1076 resources available
189P - Superior anti-tumor activity of NC18, a novel HER2-targeting ADC, against enhertu-resistant CDX model
Presenter: Li Zhi
Session: Poster Display session
Resources:
Abstract
190P - Tislelizumab as a treatment for Esophageal carcinoma: A systematic review and meta-analysis
Presenter: Hashim Talib Hashim
Session: Poster Display session
Resources:
Abstract
191P - Real-world data of non-metastatic carcinoma esophagus patients treated with multimodality treatment in a resource constrained setting from South India
Presenter: Ravi Teja Matta
Session: Poster Display session
Resources:
Abstract
192P - Exploring EHMT2 modulation by niclosamide in esophageal squamous cell carcinoma
Presenter: I-Chen Wu
Session: Poster Display session
Resources:
Abstract
193P - DCLK1’s kinase activity drives its pro-stemness effect in esophageal squamous cell carcinoma
Presenter: Yuping Yang
Session: Poster Display session
Resources:
Abstract
194P - Fruquintinib in combination with S-1 for ESCC patients after first-line immunotherapy failure: Update of dose-finding results
Presenter: Ningning Li
Session: Poster Display session
Resources:
Abstract
196P - Perioperative FLOT + immunotherapy for resectable gastric and gastroesophageal junction cancer: A systematic review and meta-analysis
Presenter: Lorenz Fort Revillas
Session: Poster Display session
Resources:
Abstract
197P - Efficacy and safety of lenvatinib plus adebrelimab combined with hepatic arterial infusion chemotherapy (HAIC) for unresectable biliary tract cancer
Presenter: Wenbo Guo
Session: Poster Display session
Resources:
Abstract
198P - The Efficacy and safety of adjuvant nivolumab therapy after neoadjuvant docetaxel plus cisplatin, 5-FU therapy for resectable locally advanced esophageal squamous cell carcinoma
Presenter: Nozomu Ogura
Session: Poster Display session
Resources:
Abstract
199P - Impact of baseline tumour burden on outcomes in EMERALD-1: A phase III study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in embolisation-eligible unresectable hepatocellular carcinoma (uHCC)
Presenter: Masatoshi Kudo
Session: Poster Display session
Resources:
Abstract